COVID-19 Update: Information and resources can be found here.

Radiation Therapy for Kidney Cancer

UT Southwestern offers multiple options for managing kidney cancer with radiation therapy. These treatments, which are not routinely offered elsewhere, include:

    • A combination of immunotherapy and stereotactic ablative radiotherapy (SABR) for metastatic kidney cancer (currently offered in several clinical trials with different drugs such as IL2, nivolumab, or a combination of nivolumab/ipilimumab).
      • Treatment of individual metastasis with SABR to avoid the side effects of drugs. Available for patients with a limited number of metastases in a clinical trial or even outside of a clinical trial.
        • UTSW has possibly the largest experience using SABR for the treatment of metastases. (Wang et al., Int J of Radiat Oncol, Biology, and Physics, 2017). 
        • Curative treatment with SABR for early-stage kidney cancer (currently offered in a clinical trial).
        • Treatment of tumors invading into large veins (specifically, the inferior vena cava, a main source of blood drainage into the heart) with SABR.
          • UTSW investigators were the first to report the successful use of SABR to treat tumors invading into the vena cava (Hannan et al., Cancer Biol Ther, 2015). Press Release
          • In addition, a clinical trial is ongoing to evaluate SABR treatment of tumor thrombus prior to surgery.Treatment of individual metastasis with SABR to avoid the side effects of drugs. Available for patients with a limited number of metastases in a clinical trial or even outside of a clinical trial.